TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Keytruda (Pembrolizumab)

Keytruda / Pembrolizumab. Used for selected cancers such as melanoma and lung cancer, depending on cancer type, stage or biomarkers.

PMDAproduct-level source2026-09label updated2026-10-05site verified
キイトルーダ点滴静注100mg · 100 mg / 4 mL
Japanese product photo · 100 mg / 4 mL · MSD Connect
Main useUsed for selected cancers such as melanoma and lung cancer, depending on cancer type, stage or biomarkers.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
キイトルーダ点滴静注100mg
Brand
Keytruda
Generic name
Pembrolizumab
Japanese generic name
ペムブロリズマブ
Chinese name
帕博利珠单抗
Marketing authorization holder
MSD株式会社
Strengths
100 mg
Dosage form
IV infusion
Therapeutic area
Oncology
Regulatory status
Rx
Label updated
2026-09
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Keytruda is a humanized anti-PD-1 antibody. This record covers the Japanese 100 mg intravenous vial.

Read source section ↗
02

Mechanism of action

Blocks PD-1 signaling. PD-L1, MSI/MMR or TMB testing is relevant to selected indications, with different eligibility rules.

Read source section ↗
03

Japanese indications & eligibility

Japanese indications include selected solid tumors and lymphomas, including biomarker-defined uses and some perioperative regimens.

Read source section ↗
04

Administration & dose differences

Common adult schedules are 200 mg every three weeks or 400 mg every six weeks, infused over 30 minutes.

Read source section ↗
05

Adverse effects & key risks

Monitor immune-related lung, bowel, liver, kidney, endocrine, cardiac and skin events, plus infusion reactions.

Read source section ↗
06

Contraindications & special populations

Ingredient hypersensitivity is contraindicated; review autoimmune disease, transplant, infection, lung disease and pregnancy.

Read source section ↗
07

Drug interactions

Check each combination partner and coordinate immunosuppressive therapy with the oncology team.

Read source section ↗
08

Assessment & monitoring

Follow laboratory results, symptoms and tumor response. A qualifying biomarker does not guarantee benefit.

Read source section ↗
09

Storage & handling

Store unopened vials at 2–8°C, protect from light and do not freeze.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.